Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres. In order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease. The multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.
National, Prospective, Multicentric Registry. Patients with a diagnosis of MMVD identified by echocardiography will be included and followed up at 1, 2, 3 and 5 years.
Study Type
OBSERVATIONAL
Enrollment
1,000
Chu Lille- Hopital Cardiologique
Lille, France
Chu Lariboisiere (Aphp)
Paris, France
To assess the association between cardiovascular imaging parameters (echocardiography and/or cardiac MRI) and cardiovascular event-free survival in a population of MMVD.
Survival without cardiovascular event
Time frame: 1 year after inclusion
To assess the association between cardiovascular imaging parameters and survival
Time frame: at 1, 2, 3 and 5 years after inclusion
Proportion of patients who did not experience a cardiovascular event
Time frame: at 1, 2, 3 and 5 years after inclusion
Proportion of patients who are alive
Time frame: at 1, 2, 3 and 5 years after inclusion
Proportion of patients who did not experience a cardiovascular event depending on the type of treatment (medical, surgical or percutaneous)
Time frame: at 1, 2, 3 and 5 years after inclusion
Proportion of patients who are alive depending on the type of treatment (medical, surgical or percutaneous)
Time frame: at 1, 2, 3 and 5 years after inclusion
To assess the progression of the stage of severity of valvulopathy
Echocardiography
Time frame: at 1, 2, 3 and 5 years after inclusion
% of patients with MMVD combinations
Time frame: during 5 years after inclusion
Measurement of cardiovascular biomarkers
BNP or NT-pro-BNP and troponin
Time frame: at baseline and 1, 2, 3 and 5 years after inclusion
Assessing the association between cardiovascular biomarkers in patients with MMVD and survival
BNP or NT-pro-BNP and troponin, vital status
Time frame: during 5 years after inclusion
Assessing the association between cardiovascular biomarkers in patients with MMVD and cardiovascular event-free survival
BNP or NT-pro-BNP and troponin, Survival without cardiovascular event
Time frame: during 5 years after inclusion
Exploring the value of cardiovascular biomarkers analysed in a centralised laboratory (optional)
Biobank (optional)
Time frame: at baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.